ESPR vs UPST · rev $332.3M vs P/E 74, rev $672.9M
Esperion Therapeutics Inc (ESPR) versus Upstart Holdings Inc (UPST) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Upstart Holdings Inc (UPST) is a credit services company listed on NASDAQ.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
Latest reported UPST revenue for 2026-06-30 was $672.9M. Net income was $9.9M. UPST currently screens at market cap $2.92B and trailing P/E 74.3.
ESPR currently screens at market cap $816.9M. UPST currently screens at market cap $2.92B and trailing P/E 74.3.
Not investment advice. Open the ESPR and UPST stock pages for the full models.
Not investment advice.